Inequalities in mortality following SARS-CoV-2 infection for people with severe mental illness during and following vaccination roll-out in England: a retrospective, whole-country linked cohort study.
Excess mortality in people with SMI persisted throughout the COVID-19 pandemic and preventive public health and clinical strategies are needed to address excess mortality and lower vaccination.
Abstract
Background
People with severe mental illness (SMI) had a higher risk of death following SARS-CoV-2 infection compared with people without SMI during the COVID-19 pandemic peak. It is unclear whether this risk reduced in later stages after vaccination roll-out. We aimed to assess all-cause and cause-specific mortality following SARS-CoV-2 infection in people with or without SMI across pandemic stages, using whole-country data, while accounting for sociodemographic and clinical characteristics.
Methods
In this retrospective, whole-country cohort study, we analysed linked electronic health records for all people in England registered to primary care who were alive in November, 2019 (>99% of the population). The study population included people who had COVID-19 between Jan 31, 2020, and June 30, 2023, with information on deaths and vaccination. Data extracted from the NHS England Secure Data Environment provided through the British Heart Foundation Data Science Centre CVD-COVID-UK-COVID-IMPACT Consortium linked datasets were curated to form a dataset in July, 2024. Cox regression estimated differences in all-cause and COVID-19 mortality. Analyses were stratified by pandemic stages, defined by WHO policy and UK Government vaccination roll-out: Jan 31-Sept 30, 2020 (stage 1); Oct 1, 2020-July 18, 2021 (stage 2, vaccination roll-out); and July 19, 2021-June 30, 2023 (stage 3, post-vaccination roll-out). SMI comprised schizophrenia, schizoaffective disorder, bipolar disorder, or other affective and non-affective disorder with psychosis. A patient and public involvement panel was consulted during design phases of the study.
Findings
13 463 945 people with COVID-19 were identified, of whom 160 190 (1·19%) had SMI. People with SMI were older [mean age [SD], SMI 49·7 years [17·9], non-SMI 45·0 years [17·6]), had a similar sex split (females SMI vs non-SMI: 56·3% vs 56·6%); and were mostly White British (77·3% or 76·3%). People with SMI had higher all-cause mortality than those without (adjusted hazard ratio [aHR] 1·56, 95% CI 1·53-1·59). All-cause mortality risk in people with SMI was elevated in stage 1 (aHR 1·27, 95% CI 1·22-1·32), but larger in the stage 2 (aHR 1·56, 1·51-1·61) and stage 3 (aHR 1·55, 1·50-1·59). Vaccination prevalence was initially higher for people with SMI (in stage 2: 112 795 [73·2%, 95% CI 72·9-73·4], compared with people without SMI, 8 852 970 [67·4%, 67·3-67·4]). By study end, fewer people with SMI were fully vaccinated (127 145 [79·4%, 79·2-79·6]), compared with people without SMI (11 605 915 [87·2%, 87·2-87·3]. Higher COVID-19 mortality risk in people with SMI persisted but was partially attenuated by vaccination (aHR 1·25, 1·17-1·34).
Interpretation
Excess mortality in people with SMI persisted throughout the COVID-19 pandemic. Preventive public health and clinical strategies are needed to address excess mortality and lower vaccination.
Objective: To compare the proportion of Australians living with severe mental illness (target group) and the general population (comparator group) who received the first, second, and third doses of the COVID-19 vaccination between 22 February 2021 and 30 June 2022; examine the odds of any, non-psychiatric, and COVID-19...
C. Bull, Amanda J. Wheeler, Victoria J. Palmer et al.· Australian and New Zealand j...· 1 citation
On November 23, 2021, South Australia lifted border restrictions allowing passive entry of COVID-19 cases into the community. On this date the adult South Australian population was highly vaccinated and COVID-19 naïve (prior infection rate <1:1000). There are no previous outcome data following introduction of SARS-CoV-...
Eamon Raith, Hao Z. Wong, Joshua V. Ross et al.· Health Security· 0 citations
Objective Assess associations between COVID-19 vaccine availability and differences in COVID-19 mortality risk across subgroups among 122,527 people with HIV (PWH) in Florida. Methods Analyzed HIV surveillance data, Social Vulnerability Index (SVI), and Rural-Urban Commuting Area Codes using a competing risks model to...
Tendai Gwanzura, M. Trepka, T. Li et al.· PLoS ONE· 0 citations
In the post-pandemic era, identifying children who are most susceptible to severe illness and COVID-19-related mortality is essential for guiding public health policies. This study examined the risk factors for COVID-19-related severe illness and mortality from 2023 to mid-2025. We conducted a population-based cohort s...
Laura G. Coelho, Lilian M. Diniz, Stella C. Galante et al.· Microorganisms· 0 citations
MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone, andFindings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.
Yogini V. Chudasama, S. Shabnam, K. Khunti et al.· Journal of public health· 0 citations
Background
Trends in Staphylococcus aureus bacteremia (SAB) mortality in the United States, including the impact of coronavirus disease 2019, have not been well described.
Methods
Active, laboratory- and population-based surveillance data from 20 counties (7 states) were used to examine annual, 30-day mortality rates...
Carly Adams, Holly M. Biggs, Kelly A. Jackson et al.· Open Forum Infectious Diseas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.